Extrasynaptic Site of Action for Γ-Hydroxybutyrate

Total Page:16

File Type:pdf, Size:1020Kb

Extrasynaptic Site of Action for Γ-Hydroxybutyrate Extrasynaptic site of action for γ-hydroxybutyrate S. J. Enna1 Department of Molecular and Integrative Physiology and Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical School, Kansas City, KS 66160 dvances in pharmacology often lack of concordance between the sensitiv- functional component of the [3H]GHB fi result from identifying the ity of the GABAB receptor to GHB and binding site, con rming earlier suggestions A mechanism of action of drugs the affinity of the [3H]GHB binding sites, that were based on indirect findings found empirically to be bio- with millimolar concentrations of GHB (19–21). The work by Absalom et al. (2) is γ 125 logically active (1). -Hydroxybutyric acid required to activate GABAB receptors in made possible by the synthesis of [ I]4- (GHB), also known as Fantasy, is a cen- vitro (7, 8), whereas the Kd values for the hydroxy-4-[4-(2-iodobenzyloxy)phenyl]bu- trally active agent that has been used high- and low-affinity [3H]GHB binding tanoate ([125I]BnOPh-GHB), a photo- clinically and recreationally for nearly sites are in the nanomolar and micromolar affinity label for the GHB binding site (22– half a century. Because of its history of ranges, respectively (5). These results 24). In a previous study, these investigators abuse, its availability is tightly regulated, suggest that the interaction of GHB with demonstrated that this radioligand labels fi K although it is prescribed for the treatment GABAB receptors mediates responses a single, high-af nity (7-nM d) site in rat of alcoholism and narcolepsy. Depending to high doses but contributes little to the brain membranes that displays a regional 3 on the dose, GHB displays a myriad of effects observed with lower, more clini- distribution identical to [ H]NCS-382 effects on CNS function. Despite decades cally relevant doses. binding (24). Although attachment to the of research, significant questions remain [125I]BnOPh-GHB binding site is inhibited about its mechanism of action. In PNAS, by GHB, GABA is inactive. For the Absalom et al. (2) identify a distinct pop- At least some of the study in PNAS, these investigators sub- jected the [125I]BnOPh-GHB binding ulation of extrasynaptic GABAA receptors pharmacological effects as a target for GHB, providing unique protein to proteolysis. The resultant bands insights into the molecular target for of GHB are due to its represent a variety of GABAA receptor this agent. subunits. A comprehensive functional activation of extrasynaptic screen of human recombinant GABAA GHB and GABA receptor subtypes in Xenopus oocytes re- An involvement of GABAergic systems in vealed that the most GHB-responsive site GABAA receptors. α δ β the actions of GHB has been suspected for contains 4/ - and 1-subunits. They report α δ some time because it is structurally similar that the 4/ -subunit combination is re- fi β to, and a metabolite of, GABA (3). High- Alternatively, these results might sponsible for GHB ef cacy, and the 1- 3 3 and low-affinity [ H]GHB binding sites are indicate that the [ H]GHB binding site is subunit for potency. The EC50 for GHB is present in rat and human brain (4, 5). of no physiological or pharmacological 140 nM. It is concluded that GHB is Because [3H]GHB binding is not inhibited consequence. This appears unlikely, how- a partial agonist at this site because its fi by GABA or various isosteric GABAA ever, because in vivo studies with NCS-382 maximum ef cacy at this recombinant re- receptor ligands, it appears not to attach suggest that it interacts with a functional ceptor is 74% of that displayed by GABA. to the GABA recognition site on this receptor; that is, NCS-382 administration Results from pharmacological and α-sub- pentameric, ligand-gated ion channel re- diminishes the sedative and cataleptic unit mutation experiments demonstrate ceptor. Rather, because [3H]GHB binding effects of GHB and blocks the enhancing that NCS-382 and GHB bind to the in- is influenced by chloride ions and alloste- effects on the spontaneous firing rate of terface of the β-α combination at a site ric GABAA receptor ligands, it has been cortical neurons at low doses of GHB but that overlaps with but is not identical to speculated that its site of action may be not the depressant effects seen at higher the GABAA receptor recognition site. The a component of the GABA receptor doses (14, 15). Because NCS-382 admin- finding of a significant reduction in the A B 3 chloride ion channel (6). istration blocks neither GHB-induced max for [ H]NCS-382 binding in the α δ γ-Hydroxybutyrate–induced neuronal ataxia nor its depressant effects on loco- brains of 4- but not -subunit KO mice α hyperpolarization is blocked by antago- motor activity, learned and unlearned provides further evidence that the 4-sub- nists for metabotropic, heterodimeric behavior, and operant responses (16, 17), unit is a molecular target for GHB. The authors propose that α -containing GABAB receptors (7). Studies with re- theseactionsareprobablymediatedby 4 GABA receptors, in particular α β δ, combinant GABAB receptors indicate that GHB activation of GABAB receptors. A 4 1 represent the primary site of action for GHB is a weak, isosteric GABAB receptor Efforts to characterize the GHB bind- agonist (8), as does the discovery that ing site led to the identification of GHB. The fact that the functional re- the hypolocomotion and hypothermia two parent clones (18). When expressed sponse to GHB requires the presence of a δ-subunit, which is associated with only caused by GHB are absent in GABAB in CHO cells, one of these, C12K32, receptor-deficient mice (9). However, displays NCS-382–sensitive high- and a minor fraction of GABAA receptors, but 3 β α there is no direct association between [3H] low-affinity [ H]GHB binding sites. the binding site is located at the - in- GHB binding or the binding of [3H]NCS- Characterization of the binding compo- terface, which is present in a large number 382, a GHB receptor antagonist (10–12), nent indicates a G protein-coupled site of GABAA receptors, explains why some [3H]NCS-382 binding is present after and GABAB receptors because the at- that is unassociated with either GABAA tachment of these radioligands is unaf- or GABAB receptors. fected in the brains of transgenic mice GHB and Extrasynaptic Receptors Author contributions: S.J.E. wrote the paper. lacking functional GABAB receptors. In addition, [3H]GHB binding is undetect- The study by Absalom et al. (2) provides The author declares no conflict of interest. able in GABAB receptor-transfected HEK evidence directly identifying an extra- See companion article on page 13404. 293 cells (9, 13). Moreover, there is a synaptic GABAA receptor subtype as the E-mail: [email protected]. 13142–13143 | PNAS | August 14, 2012 | vol. 109 | no. 33 www.pnas.org/cgi/doi/10.1073/pnas.1210290109 Downloaded by guest on September 29, 2021 COMMENTARY deletion of α4-subunits. An alternative sites, and are responsible for tonic in- (THIP) is an example of an extrasynaptic 3 explanation is that this residual [ H]NCS- hibition. Because of their higher affinity GABAA receptor agonist (27). Like GHB, 382 binding represents attachment to for GABA, extrasynaptic receptors are THIP activates αβδ-containing GABAA other molecularly, and possibly function- continuously activated by the small receptors and displays a range of inter- ally, distinct GHB receptors. Among these amounts of endogenous GABA present esting CNS effects. might be the G protein-coupled GHB in the local environment. Whereas the The discovery that the effects of GHB site reported by others (18). Nonetheless, most abundant synaptic receptor is are due to an interaction with extra- the findings of Absalom et al. (2) provide composed of α-, β-, and γ-subunits, the synaptic α4β1δ GABAA receptors opens direct evidence that at least some of extrasynaptic site contains α4-orα6-, β-, the way to designing more selective agents the pharmacological effects of GHB are and δ-subunits (25). Extrasynaptic GA- for this site. The synthesis of such com- due to its activation of extrasynaptic BAA receptors are targets for steroids, pounds could lead to the development GABAA receptors. ethanol, general anesthetics, convul- of a new class of drugs for the treatment Synaptic GABAA receptors mediate sants, hypnotics, and analgesics (26). of anxiety, pain, insomnia, epilepsy, fast phasic inhibition, have a lower af- The rigid GABA analog 4,5,6,7-tetrahy- and other conditions associated with finity for GABA than the extrasynaptic droisoxazolo (5,4-c)pyridine-3-(-ol) GABAergic dysfunction. 1. Enna SJ, Williams M (2009) Challenges in the search for 11. Mehta AK, Muschaweck NM, Maeda DY, Coop A, 19. Follesa P, et al. (2003) Gamma-hydroxybutyric acid and drugs to treat central nervous system disorders. J Phar- Ticku MK (2001) Binding characteristics of the diazepam antagonize a rapid increase in GABA(A) re- macol Exp Ther 329:404–411. gamma-hydroxybutyric acid receptor antagonist [(3) ceptors alpha(4) subunit mRNA abundance induced by 2. Absalom N, et al. (2012) α4βδ GABAA receptors are H](2E)-(5-hydroxy-5,7,8,9-tetrahydro-6H-benzo[a][7] ethanol withdrawal in cerebellar granule cells. Mol high-affinity targets for γ-hydroxybutyric acid (GHB). annulen-6-ylidene) ethanoic acid in the rat brain. J Pharmacol 63:896–907. Proc Natl Acad Sci USA 109:13404–13409. Pharmacol Exp Ther 299:1148–1153. 20. Cope DW, et al. (2009) Enhanced tonic GABAA inhibi- 3. Snead OC, 3rd, Furner R, Liu CC (1989) In vivo conver- 12. Castelli MP, et al. (2002) Stereoselectivity of NCS-382 tion in typical absence epilepsy.
Recommended publications
  • Summary: Traditionally, Bioanalytical Laboratories Do Not Report Actual
    Summary: Traditionally, bioanalytical laboratories do not report actual concentrations for samples with results below the limit of quantification (BLQ) in pharmacokinetic studies. BLQ values are outside the method calibration range established during validation and no data are available to support the reliability of these values. However, ignoring BLQ data can contribute to bias and imprecision in model-based pharmacokinetic analyses. From this perspective, routine use of BLQ data would be advantageous. We would like to initiate an interdisciplinary debate on this important topic by summarising the current concepts and use of BLQ data by regulators, pharmacometricians and bioanalysts. Through introducing the limit of detection and evaluating its variability BLQ data could be released and utilized appropriately for pharmacokinetic research. Keywords: Lower limit of quantification (LLOQ) Below limit of quantification (BLQ) result Limit of detection (LoD) Pharmacokinetic (PK) Pharmacodynamics (PD) Introduction Studying the effects of drugs remains central to both medical research and clinical practice. Two key branches of pharmacological analysis are (i) pharmacokinetics (PK), including drug absorption, distribution, metabolism and elimination, and (ii) pharmacodynamics (PD), exploring the effects of drugs on the living organism, including efficacy and toxicity. In PK studies the samples are collected in an effort to map the drug concentration over time in the patient. For samples collected many hours post-dose drug concentrations may be low, yet can still provide valuable information on pharmacokinetic parameters such as clearance [1,2]. Similarly, in the case of biomarker PD studies, concentrations that are too low to quantify with a particular bioanalytical method may still provide useful information. Bioanalytical laboratories define the lowest concentration that can be quantified accurately by a method as the lower limit of quantification (LLOQ).
    [Show full text]
  • ANNNNNNNNNNNNNNNNNNNN 100A 006 Left Eye Input Right Eye Input
    US 20190175049A1 ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2019 /0175049 A1 Welling ( 43 ) Pub . Date : Jun . 13 , 2019 ( 54 ) TECHNIQUES FOR ANALYZING (52 ) U . S . CI. NON -VERBAL MARKERS OF CONDITIONS CPC . .. A61B 5 /04842 (2013 . 01 ) ; A61B 5 / 7289 USING ELECTROPHYSIOLOGICAL DATA (2013 . 01) ; A61B 5 /0478 ( 2013 .01 ) ; A61B 5 /7225 ( 2013. 01 ) ; G06N 20 / 10 (2019 .01 ) (71 ) Applicant: Massachusetts Institute of Technology , Cambridge , MA (US ) ( 57 ) ABSTRACT (72 ) Inventor : Caroline Welling, Hanover, NH (US ) Embodiments related to analyzing brain activity of a subject to identify signs associated with binocular rivalry . Sensed ( 21 ) Appl. No. : 16 / 206, 639 electrical activity of a subject' s brain is received over a time period while the subject is exposed to a visual stimulus. The ( 22 ) Filed : Nov. 30 , 2018 sensed electrical activity comprises a first frequency band Related U . S . Application Data associated with a first frequency of a first image presented to the subject ' s left eye , a second frequency band associated (60 ) Provisional application No .62 / 593 , 535, filed on Dec . with a second frequency of a second image presented to the 1 , 2017 subject ' s right eye . A set of events in the time period is determined based on the frequency bands, wherein an event Publication Classification is associated with a change from a previous perceptual event (51 ) Int. Ci. to a new perceptual event. A metric for the subject is A61B 5 /0484 ( 2006 .01 ) determined based on the set of events . The metric is ana A61B 5 /00 ( 2006 .01 ) lyzed to determine whether the subject exhibits signs asso GO6N 20 / 10 (2006 .01 ) ciated with a condition that is associated with binocular A61B 5 /0478 ( 2006 .01 ) rivalry .
    [Show full text]
  • Effect of Repeated Gaboxadol Administration on Night Sleep and Next-Day Performance in Healthy Elderly Subjects
    Neuropsychopharmacology (2005) 30, 833–841 & 2005 Nature Publishing Group All rights reserved 0893-133X/05 $30.00 www.neuropsychopharmacology.org Effect of Repeated Gaboxadol Administration on Night Sleep and Next-Day Performance in Healthy Elderly Subjects 1 2 ,3 1 Stefan Mathias , Josef Zihl , Axel Steiger* and Marike Lancel 1Section of Sleep Pharmacology, Max-Planck-Institute of Psychiatry, Munich, Germany; 2Section of Neuropsychology, Max-Planck-Institute of Psychiatry, Munich, Germany; 3Department of Psychiatry, Max-Planck-Institute of Psychiatry, Munich, Germany Aging is associated with dramatic reductions in sleep continuity and sleep intensity. Since gaboxadol, a selective GABAA receptor agonist, has been demonstrated to improve sleep consolidation and promote deep sleep, it may be an effective hypnotic, particularly for elderly patients with insomnia. In the present study, we investigated the effects of subchronic gaboxadol administration on nocturnal sleep and its residual effects during the next days in elderly subjects. This was a randomized, double-blind, placebo-controlled, balanced crossover study in 10 healthy elderly subjects without sleep complaints. The subjects were administered either placebo or 15 mg gaboxadol hydrochloride at bedtime on three consecutive nights. Sleep was recorded during each night from 2300 to 0700 h and tests assessing attention (target detection, stroop test) and memory function (visual form recognition, immediate word recall, digit span) were applied at 0900, 1400, and 1700 h during the following days. Compared with placebo, gaboxadol significantly shortened subjective sleep onset latency and increased self-rated sleep intensity and quality. Polysomnographic recordings showed that it significantly decreased the number of awakenings, the amount of intermittent wakefulness, and stage 1, and increased slow wave sleep and stage 2.
    [Show full text]
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • Gaboxadol Normalizes Behavioral Abnormalities in a Mouse Model of Fragile X Syndrome
    ORIGINAL RESEARCH published: 25 June 2019 doi: 10.3389/fnbeh.2019.00141 Gaboxadol Normalizes Behavioral Abnormalities in a Mouse Model of Fragile X Syndrome Patricia Cogram 1,2,3,4, Robert M. J. Deacon 1,2,3,4, Jennifer L. Warner-Schmidt 5, Melanie J. von Schimmelmann 6, Brett S. Abrahams 6,7 and Matthew J. During 6,8* 1FRAXA-DVI, FRAXA Research Foundation, Boston, MA, United States, 2Centre for Systems Biotechnology, Biomedicine Division, Fraunhofer-Gesellschaft, Santiago, Chile, 3GEN.DDI Limited, London, United Kingdom, 4Institute of Ecology and Biodiversity (IEB), University of Chile, Santiago, Chile, 5NeuroJenic Consulting, LLC, Garden City, NY, United States, 6Ovid Therapeutics, New York, NY, United States, 7Department of Genetics and Neuroscience, Albert Einstein College of Medicine, Bronx, NY, United States, 8Department of Neurological Surgery and Molecular Virology, Immunology and Medical Genetics, Ohio State University College of Medicine, Columbus, OH, United States Fragile X syndrome (FXS) is the most common inherited form of intellectual disability and autism. FXS is also accompanied by attention problems, hyperactivity, anxiety, aggression, poor sleep, repetitive behaviors, and self-injury. Recent work supports the role of g-aminobutyric-acid (GABA), the primary inhibitory neurotransmitter in the brain, in mediating symptoms of FXS. Deficits in GABA machinery have been observed in a mouse model of FXS, including a loss of tonic inhibition in the amygdala, which is Edited by: Martine Ammassari-Teule, mediated by extrasynaptic GABAA receptors. Humans with FXS also show reduced Italian National Research Council GABAA receptor availability. Here, we sought to evaluate the potential of gaboxadol (CNR), Italy (also called OV101 and THIP), a selective and potent agonist for delta-subunit-containing Reviewed by: extrasynaptic GABA receptors (dSEGA), as a therapeutic agent for FXS by assessing Giulia Poggi, A University of Zurich, Switzerland its ability to normalize aberrant behaviors in a relatively uncharacterized mouse model Valerie J.
    [Show full text]
  • Ligand-Gated Ion Channels' British Journal of Pharmacology, Vol
    Edinburgh Research Explorer The Concise Guide to PHARMACOLOGY 2015/16 Citation for published version: Alexander, SP, Peters, JA, Kelly, E, Marrion, N, Benson, HE, Faccenda, E, Pawson, AJ, Sharman, JL, Southan, C, Davies, JA & CGTP Collaborators 2015, 'The Concise Guide to PHARMACOLOGY 2015/16: Ligand-gated ion channels' British Journal of Pharmacology, vol. 172, no. 24, pp. 5870-5903. DOI: 10.1111/bph.13350 Digital Object Identifier (DOI): 10.1111/bph.13350 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: British Journal of Pharmacology General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 05. Apr. 2019 S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: Ligand-gated ion channels. British Journal of Pharmacology (2015) 172, 5870–5903 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: Ligand-gated ion channels Stephen PH Alexander1,
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • 5-HT2A/2C Receptor Modulation of Absence Seizures and Characterization of the GHB-Model
    5-HT2A/2C receptor modulation of absence seizures and characterization of the GHB-model A thesis submitted to Cardiff University for the degree of Doctor of Philosophy by Marcello Venzi (MSc) School of Biosciences, Cardiff University, October 2014 Chapter 1 Declaration and Statements This work has not been submitted in substance for any other degree or award at this or any other university or place of learning, nor is being submitted concurrently in candidature for any degree or other award. Signed ………………………………………… (candidate) Date ………………………… STATEMENT 1 This thesis is being submitted in partial fulfillment of the requirements for the degree of PhD . Signed ………………………………………… (candidate) Date ………………………… STATEMENT 2 This thesis is the result of my own independent work/investigation, except where otherwise stated. Other sources are acknowledged by explicit references. The views expressed are my own. Signed ………………………………………… (candidate) Date ………………………… STATEMENT 3 I hereby give consent for my thesis, if accepted, to be available for photocopying and for inter- library loan, and for the title and summary to be made available to outside organisations. Signed ………………………………………… (candidate) Date ………………………… STATEMENT 4: PREVIOUSLY APPROVED BAR ON ACCESS I hereby give consent for my thesis, if accepted, to be available for photocopying and for inter- library loans after expiry of a bar on access previously approved by the Academic Standards & Quality Committee. Signed ………………………………………… (candidate) Date ………………………… II Chapter 1 Summary Absence seizures (ASs) are non-convulsive epileptic events which are common in pediatric and juvenile epilepsies. They consist of EEG generalized spike-and-wave-discharges (SWDs) accompanied by an impairment of consciousness and are expressed within the thalamocortical network.
    [Show full text]
  • Case 2:14-Cv-05824-ES-JAD Document 1 Filed 09/18/14 Page 1 of 35 Pageid: 1
    Case 2:14-cv-05824-ES-JAD Document 1 Filed 09/18/14 Page 1 of 35 PageID: 1 Charles M. Lizza William C. Baton SAUL EWING LLP One Riverfront Plaza, Suite 1520 Newark, New Jersey 07102-5426 (973) 286-6700 [email protected] Attorneys for Plaintiff Jazz Pharmaceuticals, Inc. UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY JAZZ PHARMACEUTICALS, INC., Civil Action No. ____________________ Plaintiff, COMPLAINT FOR PATENT INFRINGEMENT v. PAR PHARMACEUTICAL, INC., (Filed Electronically) Defendant. Plaintiff Jazz Pharmaceuticals, Inc. (“Jazz Pharmaceuticals”), by its undersigned attorneys, for its Complaint against defendant Par Pharmaceutical, Inc. (“Par”), alleges as follows: Nature of the Action 1. This is an action for patent infringement under the patent laws of the United States, 35 U.S.C. §100, et seq., arising from Par’s filing of an Abbreviated New Drug Application (“ANDA”) with the United States Food and Drug Administration (“FDA”) seeking ® approval to commercially market a generic version of Jazz Pharmaceuticals’ XYREM drug product prior to the expiration of United States Patent No. 8,772,306 (“the ’306 patent” or “the patent-in-suit”) owned by Jazz Pharmaceuticals. Case 2:14-cv-05824-ES-JAD Document 1 Filed 09/18/14 Page 2 of 35 PageID: 2 The Parties 2. Plaintiff Jazz Pharmaceuticals is a corporation organized and existing under the laws of the State of Delaware, having a principal place of business at 3180 Porter Drive, Palo Alto, California 94304. 3. On information and belief, defendant Par Pharmaceutical, Inc. is a corporation organized and existing under the laws of the State of Delaware, having a principal place of business at 300 Tice Boulevard, Woodcliff Lake, New Jersey.
    [Show full text]
  • ICADTS \(28-30 Août 2007, Seattle, USA\)
    Annales de Toxicologie Analytique, vol. XIX, n° 4, 2007 ORAL PRESENTATIONS RESULTS: There were 7,673 external cause deaths in Victoria between July 2000 and June 2005. Of these, COMMUNICATIONS ORALES there were 2,086 (27%) external cause deaths contained a toxicology report where alcohol was identified as positive (greater than 0). A toxicology report was not Postmortem toxicology attached in 1,420 (18.5%) cases and the remaining Toxicologie postmortem 4,152 external cause cases contained a negative result for alcohol. Of cases with a toxicology report 455 Understanding forensic toxicology in (5.4%) had a blood alcohol concentration (BAC) of less than 0.06 g/100 mL. There were 564 (7.4%) detected relation to external-cause deaths with alcohol (0.06 g/100mL to <0.16 g/100mL) and 659 J. KILLIAN(1), O. DRUMMER(2), J. OZANNE- (8.6%) had a toxic level of alcohol (>0.16 g/100 mL). SMITH(1) Of all causes with alcohol detected, 2726 (37%) were (1) Monash University Accident Research Centre, due to intentional self-harm, followed by 2005 (27%) being transport related, 932 (12%) due to poisoning and Victoria, Australia 553 (7%) being fall related. The trends and themes of (2) Monash University Department of Forensic other drugs will also be reported especially in relation Medicine and Victorian Institute of Forensic Medicine, to traffic injuries. Victoria, Australia CONCLUSIONS: The study results provide, for the AIMS: Injuries are not only recognised as an important first time in Australia, a systematic examination of the public health problem, but are also one of the major epidemiology of licit and illicit drugs in injury deaths causes of death.
    [Show full text]
  • GABA Site Agonist Gaboxadol Induces Addiction-Predicting Persistent Changes in Ventral Tegmental Area Dopamine Neurons but Is Not Rewarding in Mice Or Baboons
    5310 • The Journal of Neuroscience, April 11, 2012 • 32(15):5310–5320 Behavioral/Systems/Cognitive GABA Site Agonist Gaboxadol Induces Addiction-Predicting Persistent Changes in Ventral Tegmental Area Dopamine Neurons But Is Not Rewarding in Mice or Baboons Elena Vashchinkina,1 Anne Panhelainen,1 Olga Yu. Vekovischeva,1 Teemu Aitta-aho,1 Bjarke Ebert,2 Nancy A. Ator,3 and Esa R. Korpi1 1Institute of Biomedicine, Pharmacology, University of Helsinki, FI-00014 Helsinki, Finland, 2H. Lundbeck A/S, DK-2500 Copenhagen, Denmark, and 3Division of Behavioral Biology, Psychiatry, and Behavioral Sciences, The Johns Hopkins School of Medicine, Baltimore, Maryland 21224-6823 Dopamine neurons of the ventral tegmental area (VTA) are involved at early phases of drug addiction. Even the first in vivo dose of various abused drugs induces glutamate receptor plasticity at the excitatory synapses of these neurons. Benzodiazepines that suppress the inhibitory GABAergic interneurons in the VTA via facilitation of synaptic GABAA receptors have induced neuroplas- ticity in dopamine neurons due to this disinhibitory mechanism. Here, we have tested a non-benzodiazepine direct GABA site agonist 4,5,6,7-tetrahydroisoxazolol[4,5-c]pyridine-3-ol (THIP) (also known as gaboxadol) that acts preferentially via high- affinity extrasynaptic GABAA receptors. A single sedative dose of THIP (6 mg/kg) to mice induced glutamate receptor plasticity for at least 6 d after administration. Increased AMPA/NMDA receptor current ratio and increased frequency, amplitude, and rectifi- cation of AMPA receptor responses suggested persistent targeting of GluA2-lacking AMPA receptors in excitatory synapses of VTA ␦Ϫ/Ϫ dopamine neurons ex vivo after THIP administration.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]